Dr Roberto Iacovelli brings you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.

Prof. Roberto Iacovelli studied medicine at the “Sapienza” University of Rome, Italy. At the same University, he specialized in medical oncology and had the PhD in molecular medicine and human pathology with a focus in genitourinary cancers. He had international experience as fellow at Institute Gustave Roussy in France and he served as oncologist in main referral oncological centres in Italy. Currently, he is a medical oncologist at the Fondazione Policlinico Gemelli IRCCS in Rome, Italy. This is one of the major national hospitals with more than 1500 beds and an active Comprehensive Cancer Center.
From December 2022 he is Associate Professor of medical oncology at Sacro Cuore Catholic University of Rome, Italy.
His research activities have a focus on metastatic renal cell carcinoma, prostate and bladder cancer. His major interest is in predictive and prognostic factors in GU cancers as well as the sequence of therapy in renal cancer and the new combination of therapies in GU tumours. He participated as PI or sub-investigator in many sponsored and academic clinical trials and he published more than 150 papers in international peer-reviewed journals and several abstracts at international conferences on these topics. Dr Iacovelli received many national and international awards, such as the ASCO Cancer Foundation Merit Award in 2011 and the best poster award at the ESMO congress in 2012 and is currently a member of the Italian Guidelines in GU tumours.

Dr Roberto Iacovelli has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Arcus, Astellas, AstraZeneca, Bayer, BMS, Eisai, Ipsen, J&J, MSD, Novartis, Pfizer.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

ipcv Interactive Patient Case Video (IPCV)

Episode

1

of 1

episode
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
micro-learning Micro learning - Video, slides and more

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Oct 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

2

of 2

episode
Oncology 
Clinical implementation of testing and PARPis in combination with NHAs

Episode 2: Clinical implementation of testing and PARP inhibitors in combination with NHAs

Experts
Dr Andrew J. Armstrong
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

1

of 2

episode
Oncology 
Clinical implementation of testing and PARPi as monotherapy

Episode 1: Clinical implementation of testing and PARPi monotherapy

Experts
Dr Neal Shore
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Video podcast
Oncology 
Which mCSPC patients benefit from early treatment intensification?

A podcast from GU oncology experts

Experts
Assoc. Prof. Shilpa Gupta, Dr Fabio Schutz
  • download Downloadable
    Resources
  • clock 22 MIN
  • calendar Mar 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer
conference-update Conference update

Episode

4

of 4

episode
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education